Sanofi Offers Takeover of Aventis for $65 Billion
By Biotechdaily staff writers
Posted on 05 May 2004
In a move that would create the world's third largest pharmaceutical company and the largest in Europe, Sanofi-Synthelabo (Paris, France) has made a friendly takover bid of U.S.$65 billion in cash and stock for Aventis (Strasbourg, France), which has been approved by the Aventis board.Posted on 05 May 2004
The new company will be called Sanofi-Aventis and will rank only behind Pfizer and GaxoSmithKline in global pharmaceutical sales. The offer followed the news that Novartis (Basel, Switzerland) was interested in a merger with Sanofi-Synthelabo and will ensure that France will be home to a large pharmaceutical company, as desired by the French government.
To avoid regulatory concerns, Sanofi had earlier declared it would sell two blood-thinning drugs, Fraxiparine and Arixtra, and also the manufacturing plant in France where they are manufactured. The merger has already been approved by the European Commission.
Related Links:
Sanofi-Synthelabo
Aventis
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automatic CLIA Analyzer
Shine i6000
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
